Quiterie de Beauregard joined Medincell in 2016 and works as Head of Global Health (GH) Development to define Access Strategy in LMICs of the existing Long Acting Injectable (LAI) drug pipeline in GH and identify new projects for which Medincell’s drug delivery technology could bring significant impact. In this objective, she is in charge of identifying unmet medical needs for which a Long-Acting Injectable product could have significant impact for patients, Healthcare Providers (HCPs) and Healthcare Systems as well as defining Target Product Profiles. A part of her activity is also dedicated to defining the corporate GH strategy. Before joining Medincell, Quiterie evolved as medico-marketing manager in several pharmaceutical industries in various disease areas (Infectious Diseases, Sickle Cell Disease, Beta Thalassemia and Inflammatory Chronic Diseases) where her focus was to put in place innovative programs for patients and HCPs to improve disease management. After a 2-year course in Biology, she passed a Business School diploma (Paris). Quiterie has also been recently graduated for Global Health Supply course from the Harvard University.
